Ownership and insider activity for Cabaletta Bio, Inc. (CABA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.
Price
| Price | $2.49 |
| Market Cap | $406M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-09 | Tomasello Shawn | A-Award | 22,000 | $71K |
| 2026-06-09 | Simon Mark | A-Award | 22,000 | $71K |
| 2026-06-09 | HENRIQUES RICHARD C JR | A-Award | 22,000 | $71K |
| 2026-06-09 | Bollard Catherine | A-Award | 22,000 | $71K |
| 2026-06-09 | Brun Scott C. | A-Award | 22,000 | $71K |
| 2026-03-02 | Das Arun | A-Award | 175,000 | $578K |
| 2026-03-02 | Gerard Michael | A-Award | 175,000 | $578K |
| 2026-03-02 | Binder Gwendolyn | A-Award | 225,000 | $742K |
| 2026-03-02 | Chang David J. | A-Award | 225,000 | $742K |
| 2026-03-02 | Nichtberger Steven | A-Award | 674,000 | $2.2M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1000 | $33.0M | $136.2M | $101.4M | $122.2M | $81.6M | $193.2M | $164.0M | $83.0M |
| Short-term Investments | 0 | 0 | 0 | $7.2M | 0 | $24.9M | $48.0M | 0 | $50.6M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1000 | $34.0M | $140.6M | $113.5M | $124.5M | $108.8M | $244.5M | $166.7M | $138.9M |
| Property, Plant & Equipment | 0 | 0 | $815000 | $890000 | $1.4M | $7.6M | $7.5M | $16.1M | $21.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1000 | $34.2M | $141.5M | $114.7M | $126.3M | $117.0M | $253.7M | $185.0M | $165.1M |
| Accounts Payable | $189000 | $603000 | $920000 | $1.2M | $2.3M | $2.5M | $4.5M | $4.9M | $6.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $250000 | $943000 | $3.1M | $5.2M | $8.4M | $9.5M | $16.0M | $27.1M | $50.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.9M |
| Total Liabilities | $250000 | $44.9M | $3.1M | $5.2M | $8.4M | $12.4M | $17.5M | $32.7M | $53.0M |
| Retained Earnings | -$250000 | -$12.5M | -$33.0M | -$66.3M | -$112.6M | -$165.6M | -$233.2M | -$349.1M | -$517.0M |
| Total Equity | -$249000 | -$10.7M | $138.3M | $109.5M | $118.0M | $104.5M | $236.2M | $152.3M | $112.1M |
| Total Debt | 0 | $43.9M | 0 | 0 | 0 | $5.1M | $5.0M | $15.6M | $27.1M |
| Net Debt | -$1000 | $10.9M | -$136.2M | -$108.7M | -$122.2M | -$101.4M | -$236.2M | -$148.4M | -$106.5M |
| Working Capital | -$249000 | $33.1M | $137.4M | $108.4M | $116.2M | $99.3M | $228.5M | $139.6M | $88.7M |
Financial Health
| Debt / Equity | 0.12 |
| Current Ratio | 5.79 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.65 |
Profitability
| Return on Equity | -128.27% |
| Return on Invested Capital | -78.51% |
| Return on Assets | -70.63% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALLO · AVIR · CAPR · EDIT · HUMA · IMMP · KYTX
Explore sector: Healthcare · Biotechnology
More sections of CABA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks